Claudin18.2在胰腺癌中的表达特征及靶向治疗OA

Pancreatic cancer(PC)ranks among the leading malignancies worldwide in both incidence and mortality,and most patients are diagnosed at a locally advanced or metastatic stage.The stroma-rich tumor microenvironment of PC contributes to its immunologically"cold"phenotype.Current treatment still relies primarily on conventional chemotherapy,while responses to targeted therapy and immunotherapy remain limited,highlighting the urgent need to identify novel therapeutic targets and strategies.Claudin18.2(CLDN18.2)is a tight junction protein expressed in normal gastric mucosal epithelium and exerts biological functions by regulating paracellular permeability and maintaining epithelial barrier integrity.Breakthrough progress has already been achieved in CLDN18.2-targeted therapy for gastric cancer(GC).In recent years,studies have demonstrated that CLDN18.2 is highly expressed in PC tissues and that its expression is closely associated with tumor initiation,progression,invasion,metastasis,and patient prognosis,suggesting that CLDN18.2 may represent a promising therapeutic target.Drug development targeting CLDN18.2 has now expanded to multiple therapeutic modalities,including monoclonal antibodies,bispecific antibodies,antibody-drug conjugates,and chimeric antigen receptor T-cell therapy.A systematic review of the molecular characteristics,clinicopathological features,relevant therapeutic strategies,and emerging technological advances related to CLDN18.2 in PC may provide a theoretical reference for future basic research and clinical translation.